Answers are grounded in this paper and cite their sources.
The CD64-NVs-aPD-L1-CP could simultaneously interrupt the immunosuppressive effect of PD-L1 and decrease the inhibition of Tregs, leading to tumor growth suppression and survival time extension. Conclusion: CD64-NVs are charismatic carriers to achieve both checkpoint blockade and immunomodulatory drugs for combined cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: